$AMMJ
American Cannabis Company, Inc. Stock $ammj

$ammj Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000190359623000417 Filed on May 15, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$712.4K	$619.9K
YoY Change	14.93%	90.15%
Cost Of Revenue	$435.9K	$452.3K
YoY Change	-3.63%	218.95%
Gross Profit	$276.5K	$167.6K
YoY Change	65.03%	-9.02%
Gross Profit Margin	38.81%	27.03%
Selling, General & Admin	$708.1K	$676.5K
YoY Change	4.68%	62.09%
% of Gross Profit	256.1%	403.74%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$61.27K	$37.48K
YoY Change	63.48%	1053.23%
% of Gross Profit	22.16%	22.37%
Operating Expenses	$717.2K	$676.5K
YoY Change	6.03%	62.09%
Operating Profit	-$440.7K	-$508.9K
YoY Change	-13.4%	118.27%
Interest Expense	-$31.63K	-$27.12K
YoY Change	16.63%	14966.67%
% of Operating Profit
Other Income/Expense, Net	-$22.28K	$13.86K
YoY Change	-260.78%	1440.0%
Pretax Income	-$463.0K	-$522.2K
YoY Change	-11.33%	328.37%
Income Tax
% Of Pretax Income
Net Earnings	-$463.0K	-$522.2K
YoY Change	-11.33%	328.37%
Net Earnings / Revenue	-64.99%	-84.24%
Basic Earnings Per Share	$0.00	-$0.01
Diluted Earnings Per Share	-$0.01	-$6.255K
COMMON SHARES
Basic Shares Outstanding	85.73M shares
Diluted Shares Outstanding	85.73M shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$66.09K	$4.321M
YoY Change	-98.47%	76.88%
Cash & Equivalents	$56.50K	$4.318M
Short-Term Investments	$9.600K	$2.900K
Other Short-Term Assets	$66.19K	$1.428M
YoY Change	-95.37%	2689.9%
Inventory	$373.7K	$317.2K
Prepaid Expenses
Receivables	$354.8K	$264.9K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$860.8K	$6.331M
YoY Change	-86.4%	139.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$451.8K	$418.8K
YoY Change	7.88%	1722.54%
Goodwill	$1.332M
YoY Change
Intangibles	$1.177M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.000K	$6.000K
YoY Change	0.0%	-70.0%
Total Long-Term Assets	$3.548M	$3.140M
YoY Change	13.0%	6679.66%
TOTAL ASSETS
Total Short-Term Assets	$860.8K	$6.331M
Total Long-Term Assets	$3.548M	$3.140M
Total Assets	$4.409M	$9.471M
YoY Change	-53.45%	252.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$793.8K	$393.6K
YoY Change	101.7%	556.26%
Accrued Expenses	$65.14K	$178.5K
YoY Change	-63.5%	1368.89%
Deferred Revenue
YoY Change
Short-Term Debt	$550.0K	$550.0K
YoY Change	0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.186M	$7.073M
YoY Change	-69.1%	3715.14%
LONG-TERM LIABILITIES
Long-Term Debt	$336.6K	$550.0K
YoY Change	-38.8%
Other Long-Term Liabilities	$405.5K	$112.5K
YoY Change	260.44%
Total Long-Term Liabilities	$742.1K	$662.5K
YoY Change	12.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.186M	$7.073M
Total Long-Term Liabilities	$742.1K	$662.5K
Total Liabilities	$2.928M	$7.735M
YoY Change	-62.15%	4072.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$10.54M
YoY Change
Common Stock	$922.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.481M	$1.735M
YoY Change
Total Liabilities & Shareholders Equity	$4.409M	$9.471M
YoY Change	-53.45%	252.21%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$463.0K	-$522.2K
YoY Change	-11.33%	328.37%
Depreciation, Depletion And Amortization	$61.27K	$37.48K
YoY Change	63.48%	1053.23%
Cash From Operating Activities	-$208.6K	$3.563M
YoY Change	-105.85%	-1387.85%
INVESTING ACTIVITIES
Capital Expenditures	$39.09K	-$8.250K
YoY Change	-573.82%	68.37%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$39.09K	-$8.250K
YoY Change	373.84%	68.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$186.6K	92.46K
YoY Change	101.83%	-90.74%
NET CHANGE
Cash From Operating Activities	-$208.6K	3.563M
Cash From Investing Activities	-$39.09K	-8.250K
Cash From Financing Activities	$186.6K	92.46K
Net Change In Cash	-$61.05K	3.647M
YoY Change	-101.67%	408.89%
FREE CASH FLOW
Cash From Operating Activities	-$208.6K	$3.563M
Capital Expenditures	$39.09K	-$8.250K
Free Cash Flow	-$247.7K	$3.571M
YoY Change	-106.93%	-1414.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000945617
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent		usd
CY2023Q1	AMMJ	Debt Forgiveness DebtForgiveness		usd
CY2022Q1	AMMJ	Debt Forgiveness DebtForgiveness		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	AMMJ	Subscription Received Issued SubscriptionReceivedIssued		usd
CY2023Q1	AMMJ	Subscription Receivable Issued For Stock SubscriptionReceivableIssuedForStock		usd
CY2023Q1	AMMJ	Stock Issued During Period Value New Issues1 StockIssuedDuringPeriodValueNewIssues1		usd
CY2023Q1	AMMJ	Stockbased Compensation To Employees StockbasedCompensationToEmployees		usd
CY2023Q1	us-gaap	Increase Decrease In Intangible Assets Current IncreaseDecreaseInIntangibleAssetsCurrent		usd
CY2023Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	AMMJ	Common Stock Issued For Stock Compensation Payable CommonStockIssuedForStockCompensationPayable		usd
CY2023Q1	AMMJ	Subscription Receivable Issued For Stock SubscriptionReceivableIssuedForStock		usd
CY2023Q1	AMMJ	Less Amount Representing Interest LessAmountRepresentingInterest		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-26108
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	AMERICAN CANNABIS COMPANY, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-1116625
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Union Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste. 200
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Lakewood
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80228
CY2023Q1	dei	City Area Code CityAreaCode	303
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56497	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117547	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	354800	usd
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	974-4770
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	92152938	shares
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	469111	usd
CY2023Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	9595	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	9595	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	373736	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	352971	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	66188	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	73933	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	860815	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1023157	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	451826	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	427669	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1176909	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1223242	usd
CY2023Q1	us-gaap	Goodwill Goodwill	1332113	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1332113	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	581108	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	604020	usd
CY2023Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	6000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	6000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	3096130	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	3165375	usd
CY2023Q1	us-gaap	Assets Assets	4408771	usd
CY2022Q4	us-gaap	Assets Assets	4616201	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	793799	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	679163	usd
CY2023Q1	AMMJ	Advances From Client AdvancesFromClient	195945	usd
CY2022Q4	AMMJ	Advances From Client AdvancesFromClient	280705	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	348759	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	233348	usd
CY2023Q1	AMMJ	Stock Payable StockPayable	9086	usd
CY2022Q4	AMMJ	Stock Payable StockPayable	74343	usd
CY2023Q1	AMMJ	Right Of Use Liabilities All Current RightOfUseLiabilitiesAllCurrent	175611	usd
CY2022Q4	AMMJ	Right Of Use Liabilities All Current RightOfUseLiabilitiesAllCurrent	181661	usd
CY2023Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	112500	usd
CY2022Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	100000	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	550000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	550000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2185701	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2099220	usd
CY2022Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	75000	usd
CY2023Q1	us-gaap	Notes Payable To Bank Noncurrent NotesPayableToBankNoncurrent	336610	usd
CY2022Q4	us-gaap	Notes Payable To Bank Noncurrent NotesPayableToBankNoncurrent	150000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	405497	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	422359	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	742106	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	612960	usd
CY2023Q1	us-gaap	Liabilities Liabilities	2927807	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2746579	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	92152938	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	92152938	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92152938	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92152938	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	922	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	922	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	12023751	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11949409	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10543709	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10080709	usd
CY2023Q1	AMMJ	Total Shareholders Equity TotalShareholdersEquity	1480964	usd
CY2022Q4	AMMJ	Total Shareholders Equity TotalShareholdersEquity	1869222	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4408771	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4616201	usd
CY2023Q1	AMMJ	Consulting And Advisory Revenues ConsultingAndAdvisoryRevenues	160815	usd
CY2022Q1	AMMJ	Consulting And Advisory Revenues ConsultingAndAdvisoryRevenues	95072	usd
CY2023Q1	AMMJ	Equipment Supplies Revenues EquipmentSuppliesRevenues	363549	usd
CY2022Q1	AMMJ	Equipment Supplies Revenues EquipmentSuppliesRevenues	313144	usd
CY2023Q1	AMMJ	Cannabis Products CannabisProducts	188021	usd
CY2022Q1	AMMJ	Cannabis Products CannabisProducts	211629	usd
CY2023Q1	us-gaap	Revenues Revenues	712385	usd
CY2022Q1	us-gaap	Revenues Revenues	619845	usd
CY2023Q1	AMMJ	Cost Of Consulting And Advisory CostOfConsultingAndAdvisory	45000	usd
CY2022Q1	AMMJ	Cost Of Consulting And Advisory CostOfConsultingAndAdvisory	16407	usd
CY2023Q1	AMMJ	Cost Of Equipment Supplies CostOfEquipmentSupplies	217567	usd
CY2022Q1	AMMJ	Cost Of Equipment Supplies CostOfEquipmentSupplies	246220	usd
CY2023Q1	AMMJ	Cost Of Cannabis Product CostOfCannabisProduct	173309	usd
CY2022Q1	AMMJ	Cost Of Cannabis Product CostOfCannabisProduct	189671	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	435876	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	452298	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	276509	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	167547	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	643604	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	592320	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	64535	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	53102	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9086	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	31035	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	717225	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	676457	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-440716	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-508910	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-31634	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-27123	usd
CY2023Q1	us-gaap	Other Income OtherIncome	9350	usd
CY2022Q1	us-gaap	Other Income OtherIncome	13858	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-22284	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13265	usd
CY2023Q1	AMMJ	Net Loss NetLoss	-463000	usd
CY2022Q1	AMMJ	Net Loss NetLoss	-522175	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-463000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-522175	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q1	AMMJ	Basic And Diluted Weighted Average Common Shares Outstanding BasicAndDilutedWeightedAverageCommonSharesOutstanding	85727938	shares
CY2022Q1	AMMJ	Basic And Diluted Weighted Average Common Shares Outstanding BasicAndDilutedWeightedAverageCommonSharesOutstanding	83484049	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	2118981	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	46207	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	92463	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-522175	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1735476	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1869622	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	74342	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-463000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1480964	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-463000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-522175	usd
CY2023Q1	us-gaap	Depreciation Depreciation	61271	usd
CY2022Q1	us-gaap	Depreciation Depreciation	37482	usd
CY2022Q1	AMMJ	Stockbased Compensation To Employees StockbasedCompensationToEmployees	31035	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-114311	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	253609	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	20765	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	38609	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7743	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1377074	usd
CY2023Q1	AMMJ	Right To Use Lease Asset1 RightToUseLeaseAsset1	-22912	usd
CY2022Q1	AMMJ	Right To Use Lease Asset1 RightToUseLeaseAsset1	-39706	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	114636	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	150879	usd
CY2023Q1	AMMJ	Advances From Clients AdvancesFromClients	84760	usd
CY2022Q1	AMMJ	Advances From Clients AdvancesFromClients	-5589067	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	124498	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	58599	usd
CY2023Q1	AMMJ	Increase Decrease In Litigation Settlement Liability IncreaseDecreaseInLitigationSettlementLiability	-62500	usd
CY2022Q1	AMMJ	Increase Decrease In Litigation Settlement Liability IncreaseDecreaseInLitigationSettlementLiability	-112500	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-22912	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-39706	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-208565	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	3563095	usd
CY2023Q1	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	39092	usd
CY2022Q1	us-gaap	Property Plant And Equipment Disposals PropertyPlantAndEquipmentDisposals	1122	usd
CY2022Q1	us-gaap	Increase Decrease In Intangible Assets Current IncreaseDecreaseInIntangibleAssetsCurrent	7123	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39092	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8245	usd
CY2022Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	92463	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	186610	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	186610	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	92463	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-61048	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3647313	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117547	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	670423	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56497	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4317736	usd
CY2022Q1	AMMJ	Common Stock Issued For Stock Compensation Payable CommonStockIssuedForStockCompensationPayable	42607	usd
CY2022Q1	AMMJ	Subscription Receivable Issued For Stock SubscriptionReceivableIssuedForStock	25165	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zJKUefwpbEA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_86B_z1qR4qKuPMwc">Use of Estimates in Financial Reporting</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of unaudited consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the consolidated financial statements during the periods presented. Actual results could differ from these estimates. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period in which they are deemed to be necessary. Significant estimates made in the accompanying consolidated financial statements include but are not limited to following those related to revenue recognition, allowance for doubtful accounts and unbilled services, lives and recoverability of equipment and other long-lived assets, the allocation of the asset purchase price, contingencies, and litigation. The Company is subject to uncertainties, such as the impact of future events, economic, environmental, and political factors, and changes in the business climate; therefore, actual results may differ from those estimates. When no estimate in a given range is deemed to be better than any other when estimating contingent liabilities, the low end of the range is accrued. Accordingly, the accounting estimates used in the preparation of the Company's consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as the Company's operating environment changes. Changes in estimates are made when circumstances warrant. Such changes and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zG4aqH0U8Lag" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_86A_zG5TiALfifUg">Significant Clients and Customers</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31, 2023, three customers accounted for 43.4% of the Company’s total revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">During the three months ended March 31, 2022, three customers accounted for 42.5% of the Company’s total revenues.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023Q1	AMMJ	Related Party Transactions RelatedPartyTransactions	<p id="xdx_845_ecustom--RelatedPartyTransactions_zEEan0SgaJG8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_862_ztYhKb8tt9Wh">Related Party Transactions</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company follows FASB ASC subtopic 850-10, <i>Related Party Disclosures,</i> for the identification of related parties and disclosure of related party transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023Q1	AMMJ	Impact Of Covid19 Pandemic ImpactOfCovid19Pandemic	<p id="xdx_849_ecustom--ImpactOfCovid19Pandemic_zo6W5UHkZ1Q4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i><span id="xdx_867_zpiHLDrAaIk1">Impact of COVID-19 Pandemic</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">On March 11, 2020<i>, </i>the World Health Organization declared the current coronavirus (“COVID-<i>19”</i>) outbreak to be a global pandemic. In response to this declaration and the rapid spread of COVID-<i>19</i> within the United States, federal, state, and local governments throughout the country have imposed varying degrees of restrictions on social and commercial activity to promote social distancing in an effort to slow the spread of the illness. These measures had a significant adverse impact on many sectors of the economy, including retail commerce.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In response to state and local measures and for the protection of both employees, the Company made required changes to operations, which did not have a material impact on operations or the financial condition of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">While the state and local governments have eased restrictions on restrictions and activities, it is possible that a resurgence in COVID-<i>19</i> cases could prompt a return to or new tighter restrictions to be instituted in the future. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of these unaudited consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets	15000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	72172	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipment	26715	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets	6000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets	119887	usd
CY2023Q1	us-gaap	Finite Lived Trademarks Gross FiniteLivedTrademarksGross	660000	usd
CY2023Q1	us-gaap	Finite Lived License Agreements Gross FiniteLivedLicenseAgreementsGross	810000	usd
CY2023Q1	AMMJ	Finite Lived Intangible Assets Gross Asset FiniteLivedIntangibleAssetsGrossAsset	1470000	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	1332113	usd
CY2023Q1	us-gaap	Asset Acquisition Contingent Consideration Liability AssetAcquisitionContingentConsiderationLiability	2912000	usd
CY2023Q1	us-gaap	Accounts Receivable Gross AccountsReceivableGross	354800	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	469111	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	16071	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4071	usd
CY2023Q1	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	338729	usd
CY2022Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	465040	usd
CY2023Q1	AMMJ	Advance From Clients AdvanceFromClients	280705	usd
CY2022Q4	AMMJ	Advance From Clients AdvanceFromClients	111892	usd
CY2023Q1	AMMJ	Additional Deposits Received AdditionalDepositsReceived	79615	usd
CY2022Q4	AMMJ	Additional Deposits Received AdditionalDepositsReceived	691769	usd
CY2023Q1	AMMJ	Less Deposits Recognized As Revenue LessDepositsRecognizedAsRevenue	-164375	usd
CY2022Q4	AMMJ	Less Deposits Recognized As Revenue LessDepositsRecognizedAsRevenue	-522663	usd
CY2023Q1	AMMJ	Advance From Client AdvanceFromClient	195945	usd
CY2022Q4	AMMJ	Advance From Client AdvanceFromClient	280705	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	39555	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	38464	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	286157	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	206306	usd
CY2023Q1	AMMJ	Finished Goods Soil FinishedGoodsSoil	8843	usd
CY2022Q4	AMMJ	Finished Goods Soil FinishedGoodsSoil	66557	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	39181	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	41644	usd
CY2023Q1	AMMJ	Total Inventory TotalInventory	373736	usd
CY2022Q4	AMMJ	Total Inventory TotalInventory	352971	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	580423	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	427432	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	128597	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	113650	usd
CY2023Q1	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	451826	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	313782	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1488	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	301555	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1176909	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1488	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	255222	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1223242	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	186000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	186000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	186000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	145997	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	54000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	757997	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	65142	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	39130	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	39880	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	22029	usd
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	4302	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	3931	usd
CY2023Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	239346	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	168258	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	348760	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	233348	usd
CY2022Q4	AMMJ	Stock Payable Amounts StockPayableAmounts	74342	usd
CY2022	AMMJ	Additional Expensed Incurred Amount AdditionalExpensedIncurredAmount	9086	usd
CY2023Q1	AMMJ	Payments Upon Issuance Of Shares PaymentsUponIssuanceOfShares	-74342	usd
CY2023Q1	AMMJ	Stock Payable Amounts StockPayableAmounts	9086	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	581108	usd
CY2023Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	581108	usd
CY2023Q1	AMMJ	Present Value Of Future Minimum Lease Payments PresentValueOfFutureMinimumLeasePayments	581108	usd
CY2023Q1	AMMJ	Current Obligations Under Leases CurrentObligationsUnderLeases	-175611	usd
CY2023Q1	us-gaap	Capital Lease Obligations CapitalLeaseObligations	405497	usd

Files In Submission

Name	View Source	Status
ammj-20230331_lab.xml	Edgar Link	unprocessable
ammj-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ammj-20230331_cal.xml	Edgar Link	unprocessable
ammj-20230331_def.xml	Edgar Link	unprocessable
0001903596-23-000417-index-headers.html	Edgar Link	pending
0001903596-23-000417-index.html	Edgar Link	pending
0001903596-23-000417.txt	Edgar Link	pending
0001903596-23-000417-xbrl.zip	Edgar Link	pending
ammj-20230331.xsd	Edgar Link	pending
ammj_10q.htm	Edgar Link	pending
ex31.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
ammj_10q_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMMJ
American Cannabis Company, Inc. Stock $ammj

2023 Q1 Form 10-Q Financial Statement

#000190359623000417 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMMJ American Cannabis Company, Inc. Stock $ammj

2023 Q1 Form 10-Q Financial Statement

#000190359623000417 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMMJ
American Cannabis Company, Inc. Stock $ammj